Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

VELPATASVIR: 54 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
54
Total FAERS Reports
8 (14.8%)
Deaths Reported
9
Hospitalizations
54
As Primary/Secondary Suspect

First Report: 2017 · Latest Report: 20170202

What Are the Most Common VELPATASVIR Side Effects?

#1 Most Reported
Fatigue
15 reports (27.8%)
#2 Most Reported
Headache
12 reports (22.2%)
#3 Most Reported
Anaemia
12 reports (22.2%)

All VELPATASVIR Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Fatigue 15 27.8% 4 2
Anaemia 12 22.2% 4 0
Headache 12 22.2% 4 1
Nausea 10 18.5% 2 0
Treatment failure 10 18.5% 0 0
Hepatitis c 9 16.7% 0 0
Pruritus 9 16.7% 1 0
Insomnia 8 14.8% 1 1
Hepatocellular carcinoma 7 13.0% 2 0
Hyperbilirubinaemia 7 13.0% 3 0
Alanine aminotransferase increased 6 11.1% 2 1
Ascites 6 11.1% 2 1
Asthenia 6 11.1% 2 0
Hepatic failure 6 11.1% 3 0
Abdominal pain 5 9.3% 1 1
Arthralgia 5 9.3% 1 1
Diarrhoea 5 9.3% 1 0
Drug ineffective 5 9.3% 1 0
Gastrointestinal haemorrhage 5 9.3% 1 0
Rash 5 9.3% 1 1

Who Reports VELPATASVIR Side Effects? Age & Gender Data

Gender: 12.9% female, 87.1% male. Average age: 58.9 years. Most reports from: US. View detailed demographics →

Is VELPATASVIR Getting Safer? Reports by Year

YearReportsDeathsHosp.
2017 2 0 1

View full timeline →

What Is VELPATASVIR Used For?

IndicationReports
Chronic hepatitis c 25
Hepatitis c 25

Official FDA Label for VELPATASVIR

Official prescribing information from the FDA-approved drug label.